FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 707 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients... June 4, 2025 Efficacy of Tivozanib Monotherapy in the Post-ICI Setting Among Patients with... October 9, 2024 ESMO Gynaecological Cancers Congress 2025, Vienna, Austria, 19-21 June June 5, 2025 Young Women with Breast Cancer Often Forgo Hormone Therapy Due to... May 1, 2021 Load more HOT NEWS Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in... Woman Helps Students With Special Needs Achieve Success After Graduation American Cancer Society Report Shows Economic, Racial Disparities in Cancer Outcomes Cancer in My Community: Overcoming Inequities in Care in Argentina
